China Biotech Dealmaking Shifts from Opportunistic to Strategic

The “High Tide: China’s Innovation and Global Partnerships” session at BIO-Europe Spring 2026 opened against a backdrop of structural market transformation that the panel wasted no time diagnosing: by some estimates, 50% of assets now licensed in by multinational pharmaceutical companies originate from China — a figure that would have been implausible a decade ago. Moderated by Josh Berlin, Head of Corporate Alliances & Business Development at BioCentury, the session featured Caroline Austin, VP and Head of Transactions and Business Development at AstraZeneca; Mike Patten, CSO at Harbour BioMed; Sue Yao, Co-Head of Business Development at Kelun-Biotech; and Debra Yu, COO at Panacea Capital. Together, they constituted arguably the highest-density concentration of China dealmaking experience on any single panel at the conference — and the discussion reflected it.

The Structural Drivers Behind China’s Dealmaking Dominance

The discussion opened with a structural diagnosis of why China has become the primary external sourcing engine for global pharma: the convergence of clinical speed, cost efficiency, and platform-level scientific output has created an asymmetric opportunity that Western companies can no longer treat as peripheral. The AstraZeneca representative — whose company has executed acquisitions such as the CAR-T player Grey Cell alongside partnerships spanning CSPC, JCO Bio, and multiple others across modalities and disease areas — framed the logic in three vectors: speed, science, and scalability. AstraZeneca has operationalized this thesis to the extent of opening a new R&D center in Beijing, a commitment that signals institutional rather than transactional intent.

The Panacea Capital representative quantified what that commitment looks like at the portfolio level. In 2025, Chinese companies executed 127 out-licensing deals with a combined total deal value of approximately $144 billion and $8 billion in upfront payments alone. The acceleration into 2026 is equally pronounced — 50 licensing deals had already closed in the first three months of the year, with $4.2 billion in upfront payments already transacted, representing roughly half of the prior year’s full-year upfront total. The clinical infrastructure underpinning this volume is concrete: clinical development in China runs approximately 40% faster and 50% cheaper on average across phases relative to Western markets — a structural cost-of-capital advantage that compounds across multi-program partnerships.

Individual deal benchmarks illustrate the magnitude of the shift. The GSK–Hutchmed transaction reached approximately $12 billion in total deal value. The Takeda–Innovent, Pfizer–LaNova, and BMS–BioNTech deals each reached billion-dollar upfront thresholds — the latter two transacted on VEGF/PD-1 bispecific assets. The Hong Kong biotech equity market has tracked this momentum, with the Hong Kong Stock Exchange biotech index outpacing NASDAQ by a factor of two, twice as many biotech IPOs on HKEX versus NASDAQ in 2025, and the 2025 Hong Kong IPO class performing three times better than its NASDAQ equivalent cohort.

Case Studies in Deal Architecture: From Option Structures to Strategic Expansion

The most granular case study on deal architecture came from the Kelun-Biotech representative, whose company’s multi-year partnership with Merck traced the full arc from cautious exploration to flagship program status. The relationship originated in 2021 — not 2022 as publicly assumed, because the initial transaction was deliberately undisclosed at Merck’s request. That first deal was structured as an option arrangement: Kelun-Biotech was required to meet defined threshold milestones before the option converted to a license, and Merck — executing its first China biotech oncology collaboration — negotiated an extended option exercise window to allow for initial validation. The strategic logic was asymmetric: Merck wanted downside protection on a novel counterparty; Kelun-Biotech needed to demonstrate that Chinese-originated ADC science could meet global development standards.

The validation arrived within three to four months — well ahead of the option window — when Kelun-Biotech presented sufficient program progress for Merck to voluntarily accelerate conversion to a full license. The dynamic the Kelun-Biotech representative described — entering the partnership with a $60 million upfront on the first deal while knowingly accepting below-market terms to open the collaboration landscape — captures a deliberate strategic trade-off: near-term economics subordinated to the long-term value of establishing proof-of-concept for China biotech dealmaking credibility.

By 2023, the relationship had expanded to a third deal covering nine ADC programs across different tumor antigen targets, with a $175 million upfront and a $150 million equity investment by Merck — a co-announcement that both parties pursued with equal eagerness, marking the inversion of the original dynamic. As of 2026, the flagship program from that collaboration has 17 active global Phase III studies and represents Merck’s single largest investment in its ongoing oncology pipeline, with Merck leadership characterizing it internally as the company’s next Keytruda. Critically, Kelun-Biotech retained China rights on approximately half of the nine programs — a negotiating outcome that reflects the company’s status as a publicly traded entity with a ~$12 billion market capitalization that cannot generate investor value through royalty-only economics.

The Kelun-Biotech representative also described the company’s biotech-to-biotech deal with Crescent Bio — a structure that illuminates an alternative pathway when neither party has the capital or geographic reach to prosecute a program alone. The transaction pivoted on complementary gaps: Kelun-Biotech held an extensive ADC portfolio with different tumor antigen targets but lacked access to a VEGF/PD-1 bispecific — a modality that post-summit data from assets like ivaluzumab had established as a near- and mid-term oncology backbone. Crescent Bio, built with strong U.S. fundraising capability and deep ADC and IO expertise, held what the Kelun-Biotech representative described as the closest available analog to ivaluzumab in terms of bispecific properties but needed China-based clinical acceleration for the VEGF/PD-1 program to stay competitive with a rapidly closing landscape.

The deal structure resolved both constraints simultaneously: Kelun-Biotech received $85 million upfront for ex-China rights to its ITGB6-targeting ADC — a preclinical asset, notable given market norms — and received China rights to Crescent Bio’s VEGF/PD-1 bispecific in return, while Crescent retained rest-of-world rights and required minimal financial co-investment from Kelun for that program’s development. The quid pro quo was speed: Crescent needed Kelun’s clinical infrastructure to compress timelines. As of the panel, INDs had been filed for both collaboration programs, with combination studies expected to initiate by year-end 2026 or early 2027.

The Harbour BioMed representative — who has operated in Shanghai for a decade and brings prior buy-side experience across BMS, Celgene, and GSK — contextualized the Newco model as a capital allocation and risk-sharing mechanism particularly suited to companies with broad pipelines that cannot fund global development across all assets simultaneously. The general architecture involves licensing an asset into a newly formed entity backed by investors and a specialist management team, who typically bring either deep therapeutic area expertise or prior knowledge of the specific program. Harbour participated in the Windward Newco alongside Kelun-Biotech, using the structure to access external capital and operational bandwidth while retaining economic participation. Of 13 China-asset Newcos formed in 2025 — up from five in 2024 and two in 2023 — Harbour was involved in multiple formations, with a second Newco announced within the month preceding the conference.

The Closing China Discount and Evolving Deal Dynamics

Within this environment of intensifying competition for Chinese assets, the AstraZeneca representative drew a precise boundary around where pricing advantages remain versus where they have evaporated. For clinically validated assets, the panel’s consensus was that any China discount has effectively closed — global competition among multinationals has normalized pricing to Western market equivalents. A modest differential may persist at the pre-clinical or pre-proof-of-concept stage, but the AstraZeneca representative characterized even that gap as narrowing. The strategic implication is that early access — relationships built before assets reach clinical validation — has become the primary source of deal economics, displacing the late-stage arbitrage that characterized the earlier wave of China dealmaking.

Chinese biotech counterparties are also arriving at the table with more structurally sophisticated asks. The AstraZeneca representative enumerated four categories of evolving demands from Chinese partners: joint development participation and input into global development governance; speed-matched decision-making from the multinational partner to leverage China’s clinical acceleration advantage; co-commercialization rights or structured options to build toward ex-China commercial capability; and full utilization provisions for platform technologies rather than asset-by-asset licensing. The last point is significant — it reflects Chinese companies’ interest in establishing technology-level relationships rather than transactional, single-asset deals, which in turn creates both deeper integration and more complex governance requirements for multinational partners.

The Harbour BioMed representative addressed Western biotech hesitation directly: the preconception that operating with Chinese counterparties requires navigating fundamentally different professional norms is not supported by practice. The majority of counterparts have trained at Western academic institutions or worked within large multinational pharma or biotech organizations, creating a shared operational vocabulary in clinical development, regulatory strategy, and deal structuring. The representative’s assessment was unambiguous — Western biotech executives not yet engaging with China are operationally behind the curve.

Future Deal Structures and the Next Innovation Cycle

Looking ahead, the Panacea Capital representative offered the most forward-looking structural prediction: the Newco formation model — which requires assembling full operational infrastructure around each asset — will give way to leaner acceleration vehicles that marry biological hypothesis with China’s technical and clinical execution capabilities without the overhead of independent company formation. The model she described functions as a directed development accelerator: source a biological insight from the global pharma ecosystem, co-prosecute it using China’s platform capabilities and R&D cost structure, and advance programs to inflection points that attract downstream partners or capital without intermediate company formation. European investors and entrepreneurs — who have been relative latecomers to this ecosystem — represent a natural constituency for this model, given their access to biology and proximity to clinical infrastructure.

On the question of China’s evolution from a “me-better” innovator to a source of first-in-class biology, the Panacea Capital representative offered a “see one, do one, teach one” framework: the collaborative structures now proliferating — in which Chinese platforms access Western biological insight in exchange for technical capabilities — will iteratively transfer disease-state knowledge into the Chinese ecosystem. Deepening clinical infrastructure across Asian hospitals, combined with accumulating real-world patient data in oncology and other areas, will eventually close the biology gap that currently concentrates novel target discovery in Western institutions. The ADC and bispecific space — where the Panacea Capital representative estimated approximately 1,000 companies in China alone, with meaningful differentiation at the payload delivery and engineering level among the leaders — represents the current vanguard of this maturation.

The panel’s most durable structural insight was that the China opportunity has outgrown the framing of cost arbitrage or asset opportunism: it now constitutes a platform-level question about where the next generation of molecular medicines will originate and how Western companies will integrate that supply into their development engines. For multinational pharma, the answer is already embedded in deal flow. For biotech, the window for building relationships ahead of clinical validation — the only remaining source of deal economics differentiation — is closing at China speed.